# Nuclide record salivary-gland-toxicity (term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/terms/salivary-gland-toxicity/>
  a schema:DefinedTerm ;
  nuclide:kind "term" ;
  schema:identifier "salivary-gland-toxicity" ;
  schema:name "Salivary gland toxicity (xerostomia) from PSMA radioligand therapy"@en ;
  schema:description "PSMA radioligand therapy can dry out the mouth because normal salivary glands pick up a small amount of the drug along with the tumour. It's very common but usually mild, and is one of the main reasons patients ask about the treatment beforehand."@en ;
  schema:url <https://nuclide.cc/terms/salivary-gland-toxicity/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215833s021s024lbl.pdf>, <https://www.ema.europa.eu/en/documents/assessment-report/pluvicto-epar-public-assessment-report_en.pdf>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9608311/> ;
  nuclide:tag "adverse effect", "PSMA therapy", "quality of life" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/isotopes/lu-177/> .